

Elizabeth Helen Kemp

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2544839/publications.pdf>

Version: 2024-02-01

108
papers

5,032
citations

71102

41
h-index

95266

68
g-index

109
all docs

109
docs citations

109
times ranked

5424
citing authors

#	ARTICLE	IF	CITATIONS
1	Immunophenotypic Analysis Reveals Differences in Circulating Immune Cells in the Peripheral Blood of Patients with Segmental and Nonsegmental Vitiligo. <i>Journal of Investigative Dermatology</i> , 2022, 142, 876-883.e3.	0.7	9
2	Patho-immunological mechanisms of vitiligo: the role of the innate and adaptive immunities and environmental stress factors. <i>Clinical and Experimental Immunology</i> , 2022, 207, 27-43.	2.6	13
3	Late-onset postsurgical hypoparathyroidism following parathyroidectomy for recurrent primary hyperparathyroidism: a case report and literature review. <i>Endocrine</i> , 2020, 69, 402-409.	2.3	0
4	Pharmacodynamic studies of nasal tetracosactide with salivary glucocorticoids for a noninvasive Short Synacthen Test. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 2692-2703.	3.6	7
5	Activating Antibodies to The Calcium-sensing Receptor in Immunotherapy-induced Hypoparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 1581-1588.	3.6	27
6	Calcium-sensing receptor autoantibody-mediated hypoparathyroidism associated with immune checkpoint inhibitor therapy: diagnosis and long-term follow-up. , 2020, 8, e000687.		21
7	Autoimmune Hypercalcemia Due to Autoantibodies Against the Calcium-sensing Receptor. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 2229-2236.	3.6	3
8	Case report: a 10-year-old girl with primary hypoparathyroidism and systemic lupus erythematosus. <i>Journal of Pediatric Endocrinology and Metabolism</i> , 2020, 33, 1231-1235.	0.9	2
9	Immune Checkpoint Inhibitor-Induced Hypoparathyroidism Associated With Calcium-Sensing Receptor-Activating Autoantibodies. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 550-556.	3.6	66
10	Immunosuppressive therapy of autoimmune hypoparathyroidism in a patient with activating autoantibodies against the calcium-sensing receptor. <i>Clinical Endocrinology</i> , 2019, 90, 214-221.	2.4	6
11	International survey on high- and low-dose synacthen test and assessment of accuracy in preparing low-dose synacthen. <i>Clinical Endocrinology</i> , 2018, 88, 744-751.	2.4	25
12	Anti-Melanoma immunity and local regression of cutaneous metastases in melanoma patients treated with monobenzone and imiquimod; a phase 2 a trial. <i>OncImmunology</i> , 2018, 7, e1419113.	4.6	29
13	Autoantibodies against the calcium-sensing receptor and cytokines in autoimmune polyglandular syndromes types 2, 3 and 4. <i>Clinical Endocrinology</i> , 2018, 88, 139-145.	2.4	12
14	Severe Symptomatic Hypocalcemia from HIV Related Hypoparathyroidism. <i>Case Reports in Endocrinology</i> , 2018, 2018, 1-4.	0.4	4
15	Calcium-Sensing Receptor Autoantibodies in Patients with Autoimmune Polyendocrine Syndrome Type 1: Epitopes, Specificity, Functional Affinity, IgG Subclass, and Effects on Receptor Activity. <i>Journal of Immunology</i> , 2018, 201, 3175-3183.	0.8	12
16	084 An investigation of Lamin A autoantibodies in vitiligo. <i>Journal of Investigative Dermatology</i> , 2017, 137, S14.	0.7	1
17	Alteration of Immune-Mechanisms by Human Microbiota and Development and Prevention of Human Diseases. <i>Journal of Immunology Research</i> , 2017, 2017, 1-2.	2.2	16
18	Genome-wide association studies of autoimmune vitiligo identify 23 new risk loci and highlight key pathways and regulatory variants. <i>Nature Genetics</i> , 2016, 48, 1418-1424.	21.4	225

#	ARTICLE	IF	CITATIONS
19	Induction of regulatory T cells: A role for probiotics and prebiotics to suppress autoimmunity. <i>Autoimmunity Reviews</i> , 2016, 15, 379-392.	5.8	107
20	Early-onset hypoparathyroidism and chronic keratitis revealing <scp>APECED</scp>. <i>Clinical Case Reports (discontinued)</i> , 2015, 3, 809-813.	0.5	4
21	The CC genotype of the ERCC 1 C118T single-nucleotide polymorphism impacts positively on the efficacy of narrowband ultraviolet B therapy for vitiligo. <i>British Journal of Dermatology</i> , 2015, 173, 324-325.	1.5	0
22	Tumour necrosis factor- β antagonists as therapies for vitiligo. <i>British Journal of Dermatology</i> , 2015, 173, 635-635.	1.5	2
23	Dominant Mutations in the Autoimmune Regulator AIRE Are Associated with Common Organ-Specific Autoimmune Diseases. <i>Immunity</i> , 2015, 42, 1185-1196.	14.3	246
24	Programmed death 1 expressing regulatory T cells in vitiligo. <i>British Journal of Dermatology</i> , 2015, 172, 847-848.	1.5	0
25	PRKDC mutations associated with immunodeficiency, granuloma, and autoimmune regulator-dependent autoimmunity. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, 1578-1588.e5.	2.9	84
26	Serological proteome analysis reveals new specific biases in the IgM and IgG autoantibody repertoires in autoimmune polyendocrine syndrome type 1. <i>Autoimmunity</i> , 2015, 48, 532-541.	2.6	4
27	<scp>IL</scp>-14 and <scp>IL</scp>-16 are expressed in the thyroid of patients with either Graves'™ disease or Hashimoto's thyroiditis. <i>Clinical Endocrinology</i> , 2015, 83, 726-732.	2.4	9
28	Association between the angiotensin-converting enzyme gene insertion/deletion polymorphism and susceptibility to systemic lupus erythematosus in an Indian population. <i>Scandinavian Journal of Rheumatology</i> , 2015, 44, 425-427.	1.1	10
29	Regulatory T cells in vitiligo: Implications for pathogenesis and therapeutics. <i>Autoimmunity Reviews</i> , 2015, 14, 49-56.	5.8	95
30	Autoimmune Hypoparathyroidism. , 2015, , 177-188.		0
31	The antibody response against <scp>MART</scp>-1 differs in patients with melanoma-associated leucoderma and vitiligo. <i>Pigment Cell and Melanoma Research</i> , 2014, 27, 1086-1096.	3.3	22
32	A Redundant Role of Human Thyroid Peroxidase Propeptide for Cellular, Enzymatic, and Immunological Activity. <i>Thyroid</i> , 2014, 24, 371-382.	4.5	25
33	Prevalence and Clinical Associations of Calcium-Sensing Receptor and NALP5 Autoantibodies in Finnish APECED Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 1064-1071.	3.6	31
34	Antithyroid hormone autoantibodies in vitiligo. <i>British Journal of Dermatology</i> , 2014, 171, 690-690.	1.5	1
35	The possible implication of the S250C variant of the autoimmune regulator protein in a patient with autoimmunity and immunodeficiency: in silico analysis suggests a molecular pathogenic mechanism for the variant. <i>Gene</i> , 2014, 549, 286-294.	2.2	13
36	Vitiligo patients from India (Mumbai) show differences in clinical, demographic and autoantibody profiles compared to patients in western countries. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, 279-286.	2.4	11

#	ARTICLE	IF	CITATIONS
37	Melanocyte antigen-specific antibodies cannot be used as markers for recent disease activity in patients with vitiligo. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, 1172-1175.	2.4	26
38	Acquired Hypocalciuric Hypercalcemia in a Patient With CKD. <i>American Journal of Kidney Diseases</i> , 2013, 62, 1151-1154.	1.9	7
39	Low Frequency of Pendrin Autoantibodies Detected Using a Radioligand Binding Assay in Patients With Autoimmune Thyroid Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, E309-E313.	3.6	7
40	Radiation-induced melanoma-associated leucoderma, systemic antimelanoma immunity and disease-free survival in a patient with advanced-stage melanoma: a case report and immunological analysis. <i>British Journal of Dermatology</i> , 2013, 168, 733-738.	1.5	18
41	The angiotensin-converting enzyme gene insertion/deletion polymorphism in Indian patients with vitiligo: a case-control study and meta-analysis. <i>British Journal of Dermatology</i> , 2013, 168, 1195-1204.	1.5	9
42	Graves' Disease, Hypoparathyroidism, Systemic Lupus Erythematosus, Alopecia, and Angioedema: Autoimmune Polyglandular Syndrome Variant or Coincidence?. <i>International Journal of Immunopathology and Pharmacology</i> , 2013, 26, 217-222.	2.1	11
43	Genome-wide association analyses identify 13 new susceptibility loci for generalized vitiligo. <i>Nature Genetics</i> , 2012, 44, 676-680.	21.4	293
44	Epitopes, avidity and IgG subclasses of tyrosine hydroxylase autoantibodies in vitiligo and alopecia areata patients. <i>British Journal of Dermatology</i> , 2012, 167, 17-28.	1.5	6
45	Demonstration of autoantibodies against tyrosine hydroxylase in patients with alopecia areata. <i>British Journal of Dermatology</i> , 2011, 165, 1236-1243.	1.5	19
46	Autoantibodies against tyrosine hydroxylase in patients with non-segmental (generalised) vitiligo. <i>Experimental Dermatology</i> , 2011, 20, 35-40.	2.9	59
47	Autoimmune Hypocalciuric Hypercalcemia Unresponsive to Glucocorticoid Therapy in a Patient with Blocking Autoantibodies against the Calcium-Sensing Receptor. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 672-680.	3.6	27
48	Comprehensive Association Analysis of Candidate Genes for Generalized Vitiligo Supports XBP1, FOXP3, and TSLP. <i>Journal of Investigative Dermatology</i> , 2011, 131, 371-381.	0.7	106
49	Genome-Wide Analysis Identifies a Quantitative Trait Locus in the MHC Class II Region Associated with Generalized Vitiligo Age of Onset. <i>Journal of Investigative Dermatology</i> , 2011, 131, 1308-1312.	0.7	62
50	First report of anti-calcium-sensing receptor antibodies in a patient with Sjogren's syndrome and primary hypoparathyroidism. <i>Rheumatology</i> , 2011, 50, 1173-1175.	1.9	6
51	Mapping of human autoantibody binding sites on the calcium-sensing receptor. <i>Journal of Bone and Mineral Research</i> , 2010, 25, 132-140.	2.8	20
52	Development of a 3D human in vitro skin co-culture model for detecting irritants in real-time. <i>Biotechnology and Bioengineering</i> , 2010, 106, 794-803.	3.3	36
53	Autoantigens in Vitiligo Identified by the Serological Selection of a Phage-Displayed Melanocyte cDNA Expression Library. <i>Journal of Investigative Dermatology</i> , 2010, 130, 230-240.	0.7	26
54	Common variants in FOXP1 are associated with generalized vitiligo. <i>Nature Genetics</i> , 2010, 42, 576-578.	21.4	95

#	ARTICLE	IF	CITATIONS
55	Variant of <i>TYR</i> and Autoimmunity Susceptibility Loci in Generalized Vitiligo. <i>New England Journal of Medicine</i> , 2010, 362, 1686-1697.	27.0	352
56	Immune/Inflammatory Aspects. , 2010, , 239-267.		1
57	Activating Autoantibodies against the Calcium-Sensing Receptor Detected in Two Patients with Autoimmune Polyendocrine Syndrome Type 1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 4749-4756.	3.6	68
58	Mapping of melanin-concentrating hormone receptor 1 B cell epitopes predicts two major binding sites for vitiligo patient autoantibodies. <i>Experimental Dermatology</i> , 2009, 18, 454-463.	2.9	15
59	Melanin-concentrating hormone and melanin-concentrating hormone receptors in mammalian skin physiopathology. <i>Peptides</i> , 2009, 30, 2071-2075.	2.4	14
60	Mutation screening of PTPN22: association of the 1858T-allele with Addison's disease. <i>European Journal of Human Genetics</i> , 2008, 16, 977-982.	2.8	81
61	Vitiligo following a combined liver-kidney transplant. <i>Nephrology Dialysis Transplantation</i> , 2008, 24, 686-688.	0.7	5
62	The Calcium-Sensing Receptor Is a Target of Autoantibodies in Patients with Autoimmune Polyendocrine Syndrome Type 1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 2107-2114.	3.6	102
63	Real-Time Detection of Stress in 3D Tissue-Engineered Constructs Using NF- κ B Activation in Transiently Transfected Human Dermal Fibroblast Cells. <i>Tissue Engineering</i> , 2007, 13, 1013-1024.	4.6	16
64	Autoimmunity as an aetiological factor in vitiligo. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2007, 21, 865-876.	2.4	124
65	Autoantibody responses to melanocytes in the depigmenting skin disease vitiligo. <i>Autoimmunity Reviews</i> , 2007, 6, 138-142.	5.8	83
66	Analysis of allelic variants in the catalase gene in patients with the skin depigmenting disorder vitiligo. <i>Biochemical and Biophysical Research Communications</i> , 2006, 345, 1586-1591.	2.1	58
67	The Non-Synonymous C1858T Substitution in the PTPN22 Gene is Associated with Susceptibility to the Severe Forms of Alopecia Areata. <i>Human Immunology</i> , 2006, 67, 535-539.	2.4	38
68	Function-blocking autoantibodies to the melanin-concentrating hormone receptor in vitiligo patients. <i>Laboratory Investigation</i> , 2006, 86, 781-789.	3.7	26
69	Structural Insights into Autoreactive Determinants in Thyroid Peroxidase Composed of Discontinuous and Multiple Key Contact Amino Acid Residues Contributing to Epitopes Recognized by Patients' Autoantibodies. <i>Endocrinology</i> , 2006, 147, 5995-6003.	2.8	19
70	A single-nucleotide polymorphism in the gene encoding lymphoid protein tyrosine phosphatase (PTPN22) confers susceptibility to generalised vitiligo. <i>Genes and Immunity</i> , 2005, 6, 584-587.	4.1	109
71	CTLA4 polymorphisms are associated with vitiligo, in patients with concomitant autoimmune diseases. <i>Pigment Cell & Melanoma Research</i> , 2005, 18, 55-58.	3.6	57
72	An insertion/deletion polymorphism in the gene encoding angiotensin converting enzyme is not associated with generalised vitiligo in an English population. <i>Archives of Dermatological Research</i> , 2005, 297, 94-98.	1.9	20

#	ARTICLE	IF	CITATIONS
73	Polymorphisms in the Cytotoxic T Lymphocyte Antigen-4 Gene Region Confer Susceptibility to Addison's Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 3474-3476.	3.6	105
74	Melanoma cell migration is upregulated by tumour necrosis factor- α and suppressed by α -melanocyte-stimulating hormone. <i>British Journal of Cancer</i> , 2004, 90, 1457-1463.	6.4	48
75	α -Melanocyte-Stimulating Hormone, MSH 11-13 KPV and Adrenocorticotrophic Hormone Signalling in Human Keratinocyte Cells. <i>Journal of Investigative Dermatology</i> , 2004, 122, 1010-1019.	0.7	45
76	Autoantibodies as Diagnostic and Predictive Markers of Vitiligo. <i>Autoimmunity</i> , 2004, 37, 287-290.	2.6	16
77	Autoantibodies in Vitiligo Patients Recognize Multiple Domains of the Melanin-Concentrating Hormone Receptor. <i>Journal of Investigative Dermatology</i> , 2003, 121, 765-770.	0.7	19
78	Detection and localization of chemokine gene expression in autoimmune thyroid disease. <i>Clinical Endocrinology</i> , 2003, 59, 207-213.	2.4	82
79	Anti-inflammatory and anti-invasive effects of α -melanocyte-stimulating hormone in human melanoma cells. <i>British Journal of Cancer</i> , 2003, 89, 2004-2015.	6.4	65
80	HLA-G does not have a pathophysiological role in Graves' disease. <i>Journal of Clinical Pathology</i> , 2003, 56, 475-477.	2.0	3
81	Immunoscreening of phage-displayed cDNA-encoded polypeptides identifies B cell targets in autoimmune disease. <i>Biochemical and Biophysical Research Communications</i> , 2002, 298, 169-177.	2.1	20
82	Inhibition of Tumor Necrosis Factor- α Stimulated NF κ B/p65 in Human Keratinocytes by α -Melanocyte Stimulating Hormone and Adrenocorticotrophic Hormone Peptides. <i>Journal of Investigative Dermatology</i> , 2002, 119, 1244-1253.	0.7	69
83	Autoantibodies in vitiligo patients are not directed to the melanocyte differentiation antigen MelanA/MART1. <i>Clinical and Experimental Immunology</i> , 2002, 129, 527-532.	2.6	24
84	The melanin-concentrating hormone receptor 1, a novel target of autoantibody responses in vitiligo. <i>Journal of Clinical Investigation</i> , 2002, 109, 923-930.	8.2	89
85	The melanin-concentrating hormone receptor 1, a novel target of autoantibody responses in vitiligo. <i>Journal of Clinical Investigation</i> , 2002, 109, 923-930.	8.2	39
86	Autoimmune Aspects of Vitiligo. <i>Autoimmunity</i> , 2001, 34, 65-77.	2.6	110
87	The Transcription Factors SOX9 and SOX10 Are Vitiligo Autoantigens in Autoimmune Polyendocrine Syndrome Type I. <i>Journal of Biological Chemistry</i> , 2001, 276, 35390-35395.	3.4	122
88	Molecular mapping of epitopes on melanocyte-specific protein Pmel17 which are recognized by autoantibodies in patients with vitiligo. <i>Clinical and Experimental Immunology</i> , 2001, 124, 509-515.	2.6	22
89	Identification of antigenic domains on the human sodium-iodide symporter which are recognized by autoantibodies from patients with autoimmune thyroid disease. <i>Clinical and Experimental Immunology</i> , 2001, 124, 377-385.	2.6	7
90	Is there loss or qualitative changes in the expression of thyroid peroxidase protein in thyroid epithelial cancer?. <i>British Journal of Cancer</i> , 2001, 85, 875-880.	6.4	20

#	ARTICLE	IF	CITATIONS
91	Localization of GerAA and GerAC Germination Proteins in the <i>Bacillus subtilis</i> Spore. Journal of Bacteriology, 2001, 183, 4317-4322.	2.2	114
92	Immunological pathomechanisms in vitiligo. Expert Reviews in Molecular Medicine, 2001, 3, 1-22.	3.9	52
93	Autoantibodies to the flavoprotein subunit of succinate dehydrogenase: analysis of specificity in autoimmune thyroid disease. Clinical Endocrinology, 2000, 53, 291-299.	2.4	6
94	Detection of Binding and Blocking Autoantibodies to the Human Sodium-Iodide Symporter in Patients with Autoimmune Thyroid Disease*. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 2020-2027.	3.6	45
95	Association Analysis of the Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) and Autoimmune Regulator-1 (AIRE-1) Genes in Sporadic Autoimmune Addison's Disease. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 688-691.	3.6	73
96	Detection of Binding and Blocking Autoantibodies to the Human Sodium-Iodide Symporter in Patients with Autoimmune Thyroid Disease. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 2020-2027.	3.6	42
97	Identification of Epitopes on Tyrosinase which are Recognized by Autoantibodies from Patients with Vitiligo. Journal of Investigative Dermatology, 1999, 113, 267-271.	0.7	30
98	Analysis of a microsatellite polymorphism of the cytotoxic T-lymphocyte antigen-4 gene in patients with vitiligo. British Journal of Dermatology, 1999, 140, 73-78.	1.5	60
99	Autoantibodies to tyrosinase-related protein-1 detected in the sera of vitiligo patients using a quantitative radiobinding assay. British Journal of Dermatology, 1998, 139, 798-805.	1.5	100
100	Autoantibodies to human melanocyte-specific protein Pmel17 in the sera of vitiligo patients: a sensitive and quantitative radioimmunoassay (RIA). Clinical and Experimental Immunology, 1998, 114, 333-338.	2.6	67
101	A cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphism is associated with autoimmune Addison's disease in English patients. Clinical Endocrinology, 1998, 49, 609-613.	2.4	97
102	Analysis of Immunoglobulin G ^o Antithyroid Peroxidase Antibodies from Different Tissues in Hashimoto's Thyroiditis. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 3818-3825.	3.6	25
103	Immunoglobulin G ^o Antithyroid Peroxidase Antibodies in Hashimoto's Thyroiditis: Epitope-Mapping Analysis. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 2639-2644.	3.6	46
104	Detection of Tyrosinase Autoantibodies in Patients With Vitiligo Using ³⁵ S-Labeled Recombinant Human Tyrosinase in a Radioimmunoassay. Journal of Investigative Dermatology, 1997, 109, 69-73.	0.7	83
105	Immunoglobulin G ^o Antithyroid Peroxidase Antibodies in Hashimoto's Thyroiditis: Epitope-Mapping Analysis. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 2639-2644.	3.6	42
106	The genetic analysis of bacterial spore germination. Journal of Applied Bacteriology, 1994, 76, 9S.	1.1	67
107	Spore germination genes of <i>Bacillus subtilis</i> 168. Research in Microbiology, 1991, 142, 847-850.	2.1	6
108	Complete nucleotide sequence and deduced amino acid sequence of the M5 polypeptide gene of <i>Escherichia coli</i> . Nucleic Acids Research, 1987, 15, 3924-3924.	14.5	9